Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy

  • Md. Selim Ahmed, Se Eun Byeon, Yideul Jeong, Mohammad Alam Miah, Md Salahuddin, Yoon Lee, Sung-Soo Park, Yong-Soo Bae
  • OncoImmunology, January 2015, Taylor & Francis
  • DOI: 10.4161/2162402x.2014.984550

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.4161/2162402x.2014.984550